Lymphatic Drainage of the Breast, a Retrospective Assessment of Data

NCT ID: NCT05064215

Last Updated: 2021-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

14 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-25

Study Completion Date

2021-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

retrospective evaluation of patients, in whom blue colour was injected into different sites of the breast before breast reduction, to investigate direction and localisation of lymphatic flow. Investigations were performed at the Wilhelminenspital, Vienna, in the years 1998 to 2009.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymph Drainage of Breast

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

injection behind NAC

in 7 breasts dye was injected behind the nipple areola complex before breast reduction

anatomical examination

Intervention Type PROCEDURE

After injection of dye, its distribution along lymphatic clearance paths was investigated

Injection into lateral upper quadrant

in 5 breasts dye was injected into upper lateral glandular tissue before breast reduction

anatomical examination

Intervention Type PROCEDURE

After injection of dye, its distribution along lymphatic clearance paths was investigated

injection into medial upper quadrant

in 2 breasts dye was injected into upper medial glandular tissue before breast reduction

anatomical examination

Intervention Type PROCEDURE

After injection of dye, its distribution along lymphatic clearance paths was investigated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anatomical examination

After injection of dye, its distribution along lymphatic clearance paths was investigated

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

\-
Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dr. Elisabeth Würinger

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Elisabeth Würinger

Dr. Elisabeth Würinger

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elisabeth Würinger

Role: PRINCIPAL_INVESTIGATOR

Dr. Elisabeth Würinger

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Elisabeth Wuringer

Vienna, Österreich, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK 21-102-VK

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Can ILR Reduce the Risk of Arm Lymphedema?
NCT05742945 ACTIVE_NOT_RECRUITING NA
Lymphovenous Anastomosis for Breast Cancer Lymphedema
NCT06302361 ACTIVE_NOT_RECRUITING NA